相关实验视频

Updated: Jun 17, 2025

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

病例报告:第三线免疫疗法对耐火性胸膜癌的持续生存益处

Mi Meng¹, Bo Yu², Jie Luo³

¹Department of Thoracic Oncology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China.

Frontiers in oncology

|August 7, 2024

概括

耐火性胸膜癌 (TC) 患者可能受益于免疫检查点抑制剂sintilimab. 一名耐化疗和放射治疗的患者通过使用sintilimab实现了17个月的部分缓解,显示出它作为可行的治疗选择的潜力.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.

背景情况:

胸膜癌 (TC) 是一种罕见的胸膜上皮瘤,在复发或耐药病例中预后不佳.
目前对晚期TC的治疗选择有限,特别是在传统疗法失败后.

研究的目的:

评估抗编程细胞死亡-1抑制剂sintilimab的疗效和安全性,作为耐火性胸膜癌患者的第三线治疗.

主要方法:

一个胸膜癌患者的病例报告.
用sintilimab (抗编程细胞死亡-1 抑制剂) 治疗化学疗法和放射治疗失败后的第三线治疗.

主要成果:

患者实现了长期的部分缓解,持续17个月.
辛提利马布治疗耐受性良好,没有报告严重不良事件.

结论:

辛提利马布显示出作为耐火性胸膜癌患者可行的和有效的治疗选择的潜力.
免疫检查点抑制剂单疗法,特别是sintilimab,可能为治疗选择有限的患者提供新的途径.

关键词:

这是一种抗PD-1药物.案例报告案例报告这种感觉是不可思议的.治疗选择是一种治疗选择.胸腺癌 (TC) 是一种

更多相关视频

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.